Novartis CRTH258C2302 Raven
Posted by: Georgia Retina in
Research Title: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Adult Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion (RAVEN) Sponsor: Novartis Pharmaceuticals Principal Investigator: Robert Stoltz, M.D., Ph.D. Description: Following a 4-week maximum screening period, patients will be randomized and…
Read More